PharmaMar, Globant collaborate to accelerate oncology research with AI

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.

July 17, 2026

Vol.52 No.28

By Paul Goldberg and Claire Marie Porter

Clinical Trials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research.

July 10, 2026

Vol.52 No.27

By Enrique Velazquez-Villarreal

AI in action: MANAscore tool moves closer to clinic

One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.

June 05, 2026

Vol.52 No.22

In Brief

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

Labcorp and the Alliance for Clinical Trials in Oncology will collaborate on a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer.

June 05, 2026

Vol.52 No.22

In Brief

Advocate Health partners with AI startup to connect more cancer patients to clinical trials

Advocate Health and Lind, an AI-powered clinical reserch platform, are partnering to help connect more cancer patients to clinical trials.

June 05, 2026

Vol.52 No.22

In Brief

OpenEvidence integrates ASCO guidelines, figures, and flowcharts into specialty oncology model

OpenEvidence announced an integration of ASCO Guidelines, figures, and flowcharts into the OpenEvidence model.

June 05, 2026

Vol.52 No.22

PharmaMar, Globant collaborate to accelerate oncology research with AI

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

AI in action: MANAscore tool moves closer to clinic

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

Advocate Health partners with AI startup to connect more cancer patients to clinical trials

OpenEvidence integrates ASCO guidelines, figures, and flowcharts into specialty oncology model

Renew today!

Subscriber content

Never miss an issue!

Login

PharmaMar, Globant collaborate to accelerate oncology research with AI

YOU MAY BE INTERESTED IN

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the wayKnudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The challenge of making the move from conversational AI to autonomous scientific discoveryAdvancing from level II to level III AI agents in precision medicine

AI in action: MANAscore tool moves closer to clinic

Labcorp and Alliance partner to support multi-institution trial to expand genetic testing in CRC

Advocate Health partners with AI startup to connect more cancer patients to clinical trials

OpenEvidence integrates ASCO guidelines, figures, and flowcharts into specialty oncology model

Never miss an issue!

Login

The Directors: Two leaders in data science have a warp speed vision for AI, with cancer clinical trials leading the way
Knudsen and Thoelke: “It’s actually solving for bottlenecks and challenges that we’ve been unable to overcome for so long”

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine